Litigation Details for Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC (D. Del. 2022)

Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC (D. Del. 2022)

Docket		Date Filed	2022-08-09
Court	District Court, D. Delaware	Date Terminated	2023-07-31
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	11,058,677; 8,168,655; 8,367,701; 8,927,574; 9,085,553; 9,353,088; 9,447,077; 9,890,141
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-08-09				External link to document

Litigation summary and analysis for: Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC (D. Del. 2022)

Last updated: July 16, 2026

Novartis v. Ingenus (1:22-cv-01045): Litigation summary, Paragraph IV posture, and exclusivity risk analysis

Novartis Pharmaceuticals Corporation vs. Ingenus Pharmaceuticals, LLC in C.D. California, Case No. 1:22-cv-01045 is a Hatch-Waxman patent dispute filed in 2022 involving Novartis drug IP and an ANDA/ANDA-type generic challenge trajectory. The filing date places the matter in the window where courts typically adjudicate patent validity and infringement for one or more Orange Book-listed patents, with outcomes that directly govern whether Ingenus can launch “at risk” or after a court-ordered forfeiture/entry trigger.

Litigation drivers to map for decision-making:

• Which Orange Book patents Novartis asserted.
• Whether the asserted claims were attacked as invalid, not infringed, or both via a Paragraph IV theory (typical for ANDA challenges).
• Whether the case reached a Markman construction stage, and if so, which terms were construed in ways that affect infringement.
• Whether any settlement occurred, including entry dates and any mutual NDA terms affecting noninfringement positions.
• Whether the court issued any injunction, PI denial/grant, or summary judgment affecting the launch calendar.

Limits note: No case docket text, complaint/answer details, or patent list were provided in the prompt, so a complete, citation-backed claim-by-claim litigation summary cannot be produced without risking inaccuracies.

What patents did Novartis assert against Ingenus in 1:22-cv-01045?

Direct answer: Not determinable from the information provided. A correct response requires the specific asserted patent numbers and asserted claim sets from the complaint or docket filings.

Which Orange Book patents are typically asserted in disputes like this?

In Hatch-Waxman cases, Novartis commonly asserts one of the following categories, depending on the product and Orange Book listing:

• Compound patents (API structure).
• Composition of matter patents (drug substance/formulation).
• Method-of-use patents (including dosing regimens).
• Manufacturing or process patents (less common for generic entry but still possible).

How to align asserted patents to exclusivity timelines

To assess exposure, each asserted patent must be mapped to:

• Patent expiration date.
• Any pediatric extension.
• Any regulatory exclusivity impact (NCE/505(b)(2) exclusivity is separate from patent term but affects launch risk).
• Whether the patent is listed as “drug substance” vs “drug product” vs “method of use” on the Orange Book.

What is the procedural posture of Novartis v. Ingenus (1:22-cv-01045)?

Direct answer: Not determinable from the information provided.

Key procedural milestones to check in the docket

For an ANDA-based Paragraph IV case, the business-critical milestones are:

• Complaint filing (assertion of patents and infringement theory).
• Answer (denials and affirmative defenses, including invalidity grounds).
• Claim construction briefing and Markman order.
• Summary judgment motions (common on infringement and §101/§102/§103/§112 issues).
• Trial (rarely reaches trial unless case is long-dated).
• Injunction or PI outcome (governs whether launch is enjoined).

Typical Hatch-Waxman timing impacts

• A fast claim construction can narrow infringement and settlement leverage.
• Adjudicated invalidity can trigger earlier generic entry.
• Denied summary judgment on invalidity often increases settlement probability but delays launch.

When does the litigation affect generic entry and exclusivity for Ingenus?

Direct answer: Not determinable from the information provided.

Entry gating mechanisms in Hatch-Waxman

Even without knowing patent numbers, the entry clock in these cases is typically governed by:

• 30-month stay expiration (if applicable based on the first Paragraph IV filing).
• Court decision on infringement/validity.
• Any settlement agreement with agreed dates.
• License or “carve-out” terms that affect market entry timing.

What outcomes most directly move the launch calendar

• Court judgment finding infringement and validity generally blocks entry until expiration or settlement.
• Court judgment of non-infringement can allow entry if remaining patents are not blocking.
• Partial victories by either side can produce segmented entry timelines.

Was this a Paragraph IV challenge, and what defenses did Ingenus raise?

Direct answer: Not determinable from the information provided.

Core defenses used in Novartis-style ANDA litigation

Common defenses include:

• Non-infringement (ANDA product does not meet claim limitations).
• Invalidity: anticipation/obviousness (prior art), lack of written description/enablement, indefiniteness, and sometimes §101.
• Inequitable conduct or prosecution history estoppel (less common post-Therasense but still pleaded).

How strong is Novartis’ patent estate against Ingenus in this case?

Direct answer: Not determinable from the information provided.

How to evaluate “strength” once patent numbers are known

Patent estate strength for a given defendant’s ANDA hinges on:

• Claim scope and breadth after claim construction.
• Whether there is prior art or known invalidity trends for those patents.
• Whether similar patents were previously litigated or sustained in related matters.
• Whether the asserted claims are “core” composition claims or narrower method/formulation claims.

What to measure for business risk

• Likelihood of invalidity based on anticipated prior art categories.
• Whether infringement depends on a measurable process parameter (harder for defendant to avoid).
• Whether the formulation is designed around design-around spaces.

What formulations or manufacturing methods were at issue?

Direct answer: Not determinable from the information provided.

Formulation patent risk frameworks

When formulation is at issue, courts often focus on:

• Particle size distribution, polymorph/solid form.
• Dissolution profile and bioavailability proxies.
• Excipients and ratios that map to claim limitations.

Manufacturing process patents center on:

• Steps and conditions (temperature/time/pressure).
• Equipment and batch controls.
• Whether the defendant’s process is “close enough” to meet claim elements.

Did the parties reach a settlement in 1:22-cv-01045?

Direct answer: Not determinable from the information provided.

Settlement terms that matter to launch strategy

When settlements occur, they usually include:

• Specific “entry date” consent or a stayed launch schedule.
• Nondesignated carve-out products.
• Payment or other consideration (terms often partially sealed).
• Dismissal with prejudice clauses.

What is the Orange Book status of the asserted patents in this dispute?

Direct answer: Not determinable from the information provided.

What Orange Book fields drive legal and commercial outcomes

• Patent numbers and expiration dates.
• Listed exclusivity code (if applicable) and whether patents are method-of-use.
• “Is listed with drug substance or drug product” designation.

How does this case compare with other Novartis generic challenges involving similar assets?

Direct answer: Not determinable from the information provided.

Comparison dimensions analysts use

• Same asserted patent family across multiple ANDA defendants.
• Whether one defendant successfully narrows claim scope via Markman outcomes.
• Whether settlement patterns cluster around shared entry dates.

What generic entry risks exist for Ingenus if Novartis loses or wins?

Direct answer: Not determinable from the information provided.

Risk map by scenario

• Novartis win (valid + infringed): Ingenus launch likely blocked until expiration of the last blocking patent or settlement carve-out.
• Ingenus win (invalid or non-infringed): Ingenus may launch earlier but can still face other unasserted patents or later-auction patents (if any).
• Mixed outcome: Launch depends on whether non-infringement or partial invalidity removes all blocking patents.

Key Takeaways

• A precise litigation summary for Novartis Pharmaceuticals Corporation v. Ingenus Pharmaceuticals, LLC (1:22-cv-01045) cannot be produced from the provided prompt because no docket facts are included (no asserted patents, no complaint allegations, no procedural orders, no settlement indication).
• For an executable business analysis, the next required fact package is the asserted patent list, claim sets, and the court’s procedural orders affecting infringement/validity. Without these items, any statement about timing, strength, or entry risk would be speculative.

FAQs

1. How do I determine whether 1:22-cv-01045 involves Paragraph IV?
2. Which Markman constructions typically swing ANDA infringement outcomes in Hatch-Waxman cases?
3. What settlement terms most often control “authorized generic” outcomes for defendants?
4. How does a court’s invalidity ruling on one asserted patent affect remaining patents in the same case?
5. What Orange Book fields are most predictive of entry timing after a dismissal or summary judgment?

References (APA)

1. None provided in the prompt.